Adma Biologics Inc (NASDAQ:ADMA) has a beta value of 0.50 and has seen 1.51 million shares traded in the recent trading session. The company, currently valued at $3.92B, closed the recent trade at $16.83 per share which meant it gained $0.38 on the day or 2.34% during that session. The ADMA stock price is -1.25% off its 52-week high price of $17.04 and 81.82% above the 52-week low of $3.06. If we look at the company’s 10-day average daily trading volume, we find that it stood at 5.01 million shares traded. The 3-month trading volume is 3.52 million shares.
The consensus among analysts is that Adma Biologics Inc (ADMA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.11.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adma Biologics Inc (NASDAQ:ADMA) trade information
Sporting 2.34% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ADMA stock price touched $16.83 or saw a rise of 1.87%. Year-to-date, Adma Biologics Inc shares have moved 272.46%, while the 5-day performance has seen it change 41.95%. Over the past 30 days, the shares of Adma Biologics Inc (NASDAQ:ADMA) have changed 25.73%. Short interest in the company has seen 8.75 million shares shorted with days to cover at 2.72.
Wall Street analysts have a consensus price target for the stock at $9.25, which means that the shares’ value could drop -81.95% from the levels at last check today. The projected low price target is $4.5 while the price target rests at a high of $14.0. In that case, then, we find that the latest price level in today’s session is 16.82% off the targeted high while a plunge would see the stock lose 73.26% from the levels at last check today.
Adma Biologics Inc (ADMA) estimates and forecasts
The company’s shares have gained 208.33% over the past 6 months, compared to 17.10% for the industry. Revenue growth from the last financial year stood is estimated to be 47.30%.
4 analysts offering their estimates for the company have set an average revenue estimate of 98.32M for the current quarter. 4 have an estimated revenue figure of 103.2M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 38.68% over the past 5 years.
ADMA Dividends
Adma Biologics Inc is expected to release its next earnings report 2024-Nov-06 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Adma Biologics Inc (NASDAQ:ADMA)’s Major holders
Insiders own 2.61% of the company shares, while shares held by institutions stand at 77.69% with a share float percentage of 79.77%. Investors are also buoyed by the number of investors in a company, with Adma Biologics Inc having a total of 310.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 18.2 million shares worth more than $120.12 million. As of 2024-03-31, BLACKROCK INC. held 8.0539% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 12.69 million shares as of 2024-03-31. The firm’s total holdings are worth over $83.75 million and represent 5.6156% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Mar 31, 2024, the former fund manager holds about 2.76% shares in the company for having 6.42 shares of worth $108.63 million while later fund manager owns 5.49 shares of worth $92.86 million as of Jun 30, 2024, which makes it owner of about 2.36% of company’s outstanding stock.
